title: The cannabinoid WIN 55,212-2 decreases specificity protein transcription factors and the oncogenic cap protein eIF4E in colon cancer cells.
abstract: 2,3-Dihydro-5-methyl-3-([morpholinyl]methyl)pyrollo(1,2,3-de)-1,4-benzoxazinyl]-[1-naphthaleny]methanone [WIN 55,212-2, (WIN)] is a synthetic cannabinoid that inhibits RKO, HT-29, and SW480 cell growth, induced apoptosis, and downregulated expression of survivin, cyclin D1, EGF receptor (EGFR), VEGF, and its receptor (VEGFR1). WIN also decreased expression of specificity protein (Sp) transcription factors Sp1, Sp3, and Sp4, and this is consistent with the observed downregulation of the aforementioned Sp-regulated genes. In addition, we also observed by RNA interference (RNAi) that the oncogenic cap protein eIF4E was an Sp-regulated gene also downregulated by WIN in colon cancer cells. WIN-mediated repression of Sp proteins was not affected by cannabinoid receptor antagonists or by knockdown of the receptor but was attenuated by the phosphatase inhibitor sodium orthovanadate or by knockdown of protein phosphatase 2A (PP2A). WIN-mediated repression of Sp1, Sp3, and Sp4 was due to PP2A-dependent downregulation of microRNA-27a (miR-27a) and induction of miR-27a-regulated ZBTB10, which has previously been characterized as an "Sp repressor." The results show that the anticancer activity of WIN is due, in part, to PP2A-dependent disruption of miR-27a:ZBTB10 and ZBTB10-mediated repression of Sp transcription factors and Sp-regulated genes, including eIF4E.
authors.affiliation: Corresponding Author: Stephen Safe, Department of Veterinary Physiology and Pharmacology, Texas A&M University, 4466 TAMU, College Station, TX 77843-4466. ssafe@cvm.tamu.edu.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Sreevalsan
authors.forename: Stephen
authors.initials: S
authors.lastname: Safe
mesh_terms: D048588:Benzoxazines / Q000494:pharmacology*; D063387:Cannabinoid Receptor Antagonists / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism*; D039561:Eukaryotic Initiation Factor-4E / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D019073:HT29 Cells; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D054648:Protein Phosphatase 2 / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D012097:Repressor Proteins / Q000378:metabolism; D051703:Sp Transcription Factors / Q000235:genetics / Q000378:metabolism*
chemical_list: D048588:Benzoxazines; D063387:Cannabinoid Receptor Antagonists; D039561:Eukaryotic Initiation Factor-4E; D035683:MicroRNAs; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; D012097:Repressor Proteins; D051703:Sp Transcription Factors; C103505:AM 251; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D054648:Protein Phosphatase 2
references.citation: Oncogene. 2012 Feb 23;31(8):1034-44
references.pmid: 21765466
references.citation: J Natl Cancer Inst. 2006 Jun 21;98(12):855-68
references.pmid: 16788159
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7691-700
references.pmid: 19047095
references.citation: J Biol Chem. 2006 Dec 22;281(51):39480-91
references.pmid: 17068343
references.citation: Drug Discov Today. 2005 Apr 1;10(7):459-62
references.pmid: 15809190
references.citation: Cell. 2009 Mar 6;136(5):823-37
references.pmid: 19269363
references.citation: J Mol Med (Berl). 2013 Apr;91(4):449-58
references.pmid: 22965195
references.citation: Biochem Biophys Res Commun. 2006 Jun 23;345(1):292-301
references.pmid: 16678129
references.citation: J Cell Biochem. 2010 May 15;110(2):321-32
references.pmid: 20336665
references.citation: Int J Obes (Lond). 2006 Apr;30 Suppl 1:S13-8
references.pmid: 16570099
references.citation: Cancer Res. 2005 Mar 1;65(5):1635-41
references.pmid: 15753356
references.citation: J Biol Chem. 2010 Aug 13;285(33):25332-44
references.pmid: 20538607
references.citation: Cancer Res. 2004 Sep 15;64(18):6740-9
references.pmid: 15374992
references.citation: Cancer Res. 2007 Nov 15;67(22):11001-11
references.pmid: 18006846
references.citation: Mol Pharmacol. 2006 Nov;70(5):1612-20
references.pmid: 16936228
references.citation: Int J Cancer. 2007 Nov 15;121(10):2172-80
references.pmid: 17583570
references.citation: Prostate. 2003 Jun 15;56(1):1-12
references.pmid: 12746841
references.citation: J Mol Med (Berl). 2008 Jan;86(1):89-98
references.pmid: 17823781
references.citation: Mol Cancer Res. 2011 Feb;9(2):195-202
references.pmid: 21156786
references.citation: Int J Cancer. 2009 Oct 15;125(8):1965-74
references.pmid: 19582879
references.citation: J Mol Med (Berl). 2012 Aug;90(8):925-34
references.pmid: 22231745
references.citation: Cancer Res. 2006 Jul 1;66(13):6748-55
references.pmid: 16818650
references.citation: Cancer Res. 2008 Aug 1;68(15):6468-76
references.pmid: 18676872
references.citation: BMC Cancer. 2011 Aug 24;11:371
references.pmid: 21864401
references.citation: Carcinogenesis. 2009 Jul;30(7):1125-31
references.pmid: 19420015
references.citation: J Biol Chem. 2000 Oct 13;275(41):31938-45
references.pmid: 10913156
references.citation: Mol Pharmacol. 2010 Aug;78(2):226-36
references.pmid: 20488920
references.citation: Br J Pharmacol. 2007 Dec;152(7):1092-101
references.pmid: 17876302
references.citation: Pharmacol Rev. 2006 Sep;58(3):389-462
references.pmid: 16968947
references.citation: Cancer Cell. 2006 Apr;9(4):301-12
references.pmid: 16616335
references.citation: Cancer Res. 2004 Aug 15;64(16):5617-23
references.pmid: 15313899
references.citation: Semin Cancer Biol. 2008 Jun;18(3):176-89
references.pmid: 18249558
references.citation: PLoS One. 2012;7(10):e48208
references.pmid: 23110215
references.citation: Cancer Res. 2008 Jan 15;68(2):339-42
references.pmid: 18199524
references.citation: Lancet Oncol. 2005 Jan;6(1):35-42
references.pmid: 15629274
references.citation: Br J Cancer. 2006 Jul 17;95(2):197-203
references.pmid: 16804518
references.citation: Mol Carcinog. 2011 Sep;50(9):655-67
references.pmid: 21268135
references.citation: EMBO J. 2004 Oct 13;23(20):4051-60
references.pmid: 15372072
references.citation: Biochem Biophys Res Commun. 2007 Feb 2;353(1):86-91
references.pmid: 17161377
references.citation: Cancer Res. 2008 Jul 1;68(13):5345-54
references.pmid: 18593936
references.citation: Cancer Res. 2007 Mar 15;67(6):2816-23
references.pmid: 17363604
references.citation: Nat Rev Cancer. 2003 Oct;3(10):745-55
references.pmid: 14570037
references.citation: Neoplasia. 2010 Oct;12(10):848-55
references.pmid: 20927323
references.citation: Mol Cancer Ther. 2012 Jul;11(7):1421-31
references.pmid: 22553354
references.citation: FASEB J. 2003 Sep;17(12):1771-3
references.pmid: 12958205
references.citation: Anticancer Res. 2011 Nov;31(11):3799-807
references.pmid: 22110202
references.citation: Mol Cancer Res. 2010 May;8(5):739-50
references.pmid: 20407012
references.citation: J Gerontol A Biol Sci Med Sci. 1996 Jan;51(1):B66-75
references.pmid: 8548503
references.citation: Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21830-5
references.pmid: 21098287